Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review

  • Jianxin TAO Department of General Surgery, Wuxi People’s Hospital, Affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, 214023, P.R. China
  • Ye ZHANG Department of General Surgery, Wuxi People’s Hospital, Affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, 214023, P.R. China
  • Tong WANG Mail Department of General Surgery, Wuxi People’s Hospital, Affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, 214023, P.R. China
Gastric cancer, Glucose transporter-1, Meta-analysis, Prognosis


Background: Glucose transporter-1 (GLUT-1) has been differentially expressed in various malignancies including gastric cancer (GC). Several previous meta-analyses of GLUT-1 have some significant limitations, such as researching the association between GLUT-1 and various cancer types with no specificity, not studying clinicopathological parameters with GLUT-1, existing conspicuous heterogeneity and so forth. Therefore, we performed a meta-analysis to evaluate the association between GLUT-1 expression and survival of gastric cancer patients, as well as clinicopathological characteristics.

Methods: We systematically searched PubMed, Embase, Web of Science and China National Knowledge Infrastructure for relevant studies in accordance with the applicable criteria up to Aug 2017. Hazard ratios (HRs) and odds ratios (ORs) with their 95% confidence intervals (CIs) were used as the effective measures.

Results: A total of 13 studies involving 1972 patients were included in this meta-analysis. The results demonstrated that there was a significant association between GLUT-1 expression and overall survival (OS) (HR=1.45, 95% CI=1.13-1.87) or disease-free survival (DFS) (HR=2.18, 95% CI=1.46-3.25). Moreover, GLUT-1 expression was significantly correlated with worse tumor nodes metastases (TNM) stage (OR=0.34, 95% CI=0.28-0.43), presence of lymph node metastasis (OR=2.88, 95% CI=1.34-6.19), intestinal type of Lauren classification (OR=3.84, 95% CI=2.57-5.74) and invasion of serosa (OR=0.25, 95% CI=0.18-0.35).

Conclusion: Our meta-analysis showed that GLUT-1 was significantly correlated with poor OS and DFS in gastric cancer. Additionally, GLUT-1 was also a potential prognostic indicator of aggressive clinicopathological parameters in gastric cancer.

Author Biography

Ye ZHANG, Department of General Surgery, Wuxi People’s Hospital, Affiliated to Nanjing Medical University, Wuxi, Jiangsu Province, 214023, P.R. China



1. Torre LA, Bray F, Siegel RL, et al (2015). Global cancer statistics, 2012. CA Cancer J Clin, 65:87-108.
2. Siegel RL, Miller KD, Jemal A (2017). Cancer Statistics, 2017. CA Cancer J Clin, 67:7-30.
3. Ajani JA (2008). Gastroesophageal cancers: progress and problems. J Natl Compr Canc Netw, 6:813-4.
4. Furuta E, Okuda H, Kobayashi A, Watabe K (2010). Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta, 1805:141-52.
5. Liberti MV, Locasale JW (2016). The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci, 41:211-218.
6. Macheda ML, Rogers S, Best JD (2005). Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol, 202:654-62.
7. Yu M, Zhou Q, Zhou Y, et al (2015). Metabolic phenotypes in pancreatic cancer. PLoS One, 10:e0115153.
8. Shen YM, Arbman G, Olsson B, Sun XF (2011). Overexpression of GLUT1 in colorectal cancer is independently associated with poor prognosis. Int J Biol Markers, 26:166-72.
9. Schmidt M, Voelker HU, Kapp M, et al (2010). Glycolytic phenotype in breast cancer: activation of Akt, up-regulation of GLUT1, TKTL1 and down-regulation of M2PK. J Cancer Res Clin Oncol, 136:219-25.
10. Goldman NA, Katz EB, Glenn AS, et al (2006). GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol, 19:1429-36.
11. Ramani P, Headford A, May MT (2013). GLUT1 protein expression correlates with unfavourable histologic category and high risk in patients with neuroblastic tumours. Virchows Arch, 462:203-9.
12. Chen X, Lu P, Zhou S, et al (2017). Predictive value of glucose transporter-1 and glucose transporter-3 for survival of cancer patients: A meta-analysis. Oncotarget, 8:13206-13213.
13. Sharen G, Peng Y, Cheng H, et al (2017). Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients. Oncotarget, 8:19760-19767.
14. Wang J, Ye C, Chen C, et al (2017). Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis. Oncotarget, 8:16875-16886.
15. Yang J, Wen J, Tian T, et al (2017). GLUT-1 overexpression as an unfavorable prognostic biomarker in patients with colorectal cancer. Oncotarget, 8:11788-11796.
16. Yu M, Yongzhi H, Chen S, et al (2017). The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis. Oncotarget, 8:43356-43367.
17. Zhao ZX, Lu LW, Qiu J, et al (2018). Glucose transporter-1 as an independent prognostic marker for cancer: a meta-analysis. Oncotarget, 9:2728-2738.
18. Moher D, Liberati A, Tetzlaff J, Altman DG (2009). Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol, 62:1006-12.
19. Stang A (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25:603-5.
20. Kim WS, Kim YY, Jang SJ, et al (2000). Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci, 15:420-4.
21. Kawamura T, Kusakabe T, Sugino T, et al (2001). Expression of glucose transporter-1 in human gastric carcinoma: association with tumor aggressiveness, metastasis, and patient survival. Cancer, 92:634-41.
22. Li W, Song X, Sun S, Zhao L (2008). Expressions of HIF-1α, Glut-1 and PCNA in gastric cancer and clinical significance. Chin J Gastroenterol Hepatol, 03:223-225.
23. Wei B, Chen L, Li J (2009). [Expression of glucose transporter 1 in gastric carcinoma and metastatic lymph nodes and its association with prognosis]. Zhonghua Wei Chang Wai Ke Za Zhi, 12:277-80.
24. Zhang P, Wu J, Zhang H, et al (2010). HIF-1α, VEGF and Glut1 protein expression in gastric carcinoma. Acta Universitatis Medicinalis Anhui, 01:86-89.
25. Alakus H, Batur M, Schmidt M, et al (2010). Variable 18F-fluorodeoxyglucose uptake in gastric cancer is associated with different levels of GLUT-1 expression. Nucl Med Commun, 31:532-8.
26. Chen Y, Liu Q, Huang J, Zhang H (2012). GLUT-1 Expression and clinicopathological significance in gastric cancer. Clinical Focus, 08:694-695.
27. Jung JH, Im S, Jung ES, Kang CS (2013). Clinicopathological implications of the expression of hypoxia-related proteins in gastric cancer. Int J Med Sci, 10:1217-23.
28. Berlth F, Monig S, Pinther B, et al (2015). Both GLUT-1 and GLUT-14 are Independent Prognostic Factors in Gastric Adenocarcinoma. Ann Surg Oncol, 22 Suppl 3:S822-31.
29. Liu Y, Liu X, Zhao L, Wu C, Li J, Shang Q (2016). Expression of Her-2, Glut1 and HIF-1α and clinical significance in primary gastric carcinoma. J Clin Exp Med, 23:2328-2330.
30. Schlosser HA, Drebber U, Urbanski A, et al (2017). Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. Gastric Cancer, 20:83-91.
31. Yang T, Hao L, Liu Y (2017). Expression of HIF-1α, GLUT-1 and LDH-5 in gastric cancer and its association with clinicopathological characteristics. J Sichuan Univ (Med Sci Edi), 01:143-146.
32. Sun Z (2017). Study of clinical significance of GLUT-1 expression in gastric cancer after radical resection. China Prac Med, 20:38-40.
33. Begg CB, Mazumdar M (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics, 50:1088-101.
34. Egger M, Davey Smith G, Schneider M, Minder C (1997). Bias in meta-analysis detected by a simple, graphical test. BMJ, 315:629-34.
35. Zhao FQ, Keating AF (2007). Functional properties and genomics of glucose transporters. Curr Genomics, 8:113-28.
36. Barron CC, Bilan PJ, Tsakiridis T, Tsiani E (2016). Facilitative glucose transporters: Implications for cancer detection, prognosis and treatment. Metabolism, 65:124-39.
37. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3:721-32.
38. Zhong H, Chiles K, Feldser D, et al (2000). Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res, 60:1541-5.
39. Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM, Semenza GL (2002). Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem, 277:38205-11.
40. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008). The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab, 7:11-20.
41. Zhang WJ, Chen C, Zhou ZH, et al (2017). Hypoxia-inducible factor-1 alpha Correlates with Tumor-Associated Macrophages Infiltration, Influences Survival of Gastric Cancer Patients. J Cancer, 8:1818-1825.
How to Cite
TAO J, ZHANG Y, WANG T. Potential Role of Glucose Transporter-1 Expression in Gastric Cancer: A Meta-Analysis and Systematic Review. Iran J Public Health. 49(11):2044-2053.
Review Article(s)